A comparison of the effectiveness of rosuvastatin, atorvastatin and simvastatin in achieving target lipid levels (according to the PROFILE-I registry)

Oleg V Gaisenok

doi:10.23950/1812-2892-jcmk-00526

Abstract

The aim of the study: was to evaluate the effectiveness of lipid-lowering therapy, depending on the choice of statin in patients with cardiovascular disease in a cohort study. Methods: Data analysis was performed in the Profile-I registry patients. The results of the examination of 148 patients were selected for the final analysis on the basis of the presence of indications for prescribing statins, the availability of data on the choice of statin and the availability of results of lipid spectrum from 274 registry patients. Results: The values of total cholesterol and LDL-С were significantly lower in the rosuvastatin group than in the atorvastatin and simvastatin groups (respectively 4.3, 4.7 and 4.6 mmol/l, p = 0.03;2.36, 2.98, and 2.66 mmol/l, p = 0.01). Conclusion: the achievement of more optimal levels of lipid spectrum turned out to be dependent on the choice of statin in this study in favor of rosuvastatin.

Highlights

The need to use statins to achieve the target levels of total cholesterol (TC), LDL-C, HDL-C and triglycerides (TG) is emphasized in international recommendations [1]
It should be noted that most studies of rosuvastatin were devoted to primary prevention of cardiovascular diseases; at the same time as atorvastatin has the greatest evidence base for secondary prevention [9,13,14,15,16]
Spearman rank correlation analysis noted a positive correlation between the increase in the dose of statin with BMI (R = 0.18, p = 0.03) and with the level of creatine phosphokinase (CPK) (R = 0.32, p = 0.009)

Summary

Introduction

The need to use statins to achieve the target levels of total cholesterol (TC), LDL-C, HDL-C and triglycerides (TG) is emphasized in international recommendations [1]. The relationship between the level of LDL and the frequency of cardiovascular complications has been proved in large studies [2,3,4,5,6,7]. The most prescribed are well-proven simvastatin, atorvastatin and rosuvastatin. The role of the latter one in influencing the regression of atherosclerosis, cardiovascular and general mortality was devoted to large-scale international studies [9,10,11,12]. It should be noted that most studies of rosuvastatin were devoted to primary prevention of cardiovascular diseases; at the same time as atorvastatin has the greatest evidence base for secondary prevention [9,13,14,15,16]

Methods

Results

Discussion

Conclusion